TAS-102 Nabs Japanese Approval for Gastric Cancer

Aug 23, 2019 – The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy, according to Taiho Pharmaceutical Co., Ltd., the manufacturer of the oral agent. The approval was based on the phase III TAGS trial, in which TAS-102 reduced the risk of death by 31% compared with placebo in patients with … (leggi tutto)